Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Tango Therapeutics Inc.

    NASDAQ: TNGX · Real-Time Price · USD
    4.70
    -0.35 (-6.93%)
    At close: Jun 13, 2025, 3:59 PM
    4.60
    -2.02%
    After-hours: Jun 13, 2025, 07:33 PM EDT

    Tango Therapeutics Statistics

    Share Statistics

    Tango Therapeutics has 108.39M shares outstanding. The number of shares has increased by 1.18% in one year.

    Shares Outstanding

    n/a
    		 108.39M

    Shares Change (YoY)

    n/a
    		 1.18%

    Shares Change (QoQ)

    n/a
    		 0.64%

    Owned by Institutions (%)

    n/a
    		 98.1%

    Shares Floating

    n/a
    		 58.92M

    Failed to Deliver (FTD) Shares

    n/a
    		 109,488

    FTD / Avg. Volume

    n/a
    		 4.99%

    Short Selling Information

    The latest short interest is 15.95M, so 14.72% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 15.95M

    Short % of Shares Out

    n/a
    		 14.72%

    Short % of Float

    n/a
    		 17.75%

    Short Ratio (days to cover)

    n/a
    		 2.51

    Valuation Ratios

    The PE ratio is -2.59 and the forward PE ratio is -3.93. Tango Therapeutics's PEG ratio is -0.25.

    PE Ratio

    n/a
    		 -2.59

    Forward PE

    n/a
    		 -3.93

    PS Ratio

    n/a
    		 8.02

    Forward PS

    n/a
    		 3.1

    PB Ratio

    n/a
    		 1.69

    P/FCF Ratio

    n/a
    		 -2.55

    PEG Ratio

    n/a
    		 -0.25
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Tango Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.98, with a Debt / Equity ratio of 0.18.

    Current Ratio

    n/a
    		 6.98

    Quick Ratio

    n/a
    		 6.98

    Debt / Equity

    n/a
    		 0.18

    Debt / EBITDA

    n/a
    		 -0.26

    Debt / FCF

    n/a
    		 -0.28

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $271,412.9

    Profits Per Employee

    n/a
    		 $-840,658.06

    Employee Count

    n/a
    		 155

    Asset Turnover

    n/a
    		 0.13

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 208K

    Effective Tax Rate

    n/a
    		 -0.16%

    Stock Price Statistics

    The stock price has increased by -47.37% in the last 52 weeks. The beta is 1.24, so Tango Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.24

    52-Week Price Change

    n/a
    		 -47.37%

    50-Day Moving Average

    n/a
    		 2.01

    200-Day Moving Average

    n/a
    		 3.87

    Relative Strength Index (RSI)

    n/a
    		 76.6

    Average Volume (20 Days)

    n/a
    		 2,194,628

    Income Statement

    In the last 12 months, Tango Therapeutics had revenue of 42.07M and earned -130.3M in profits. Earnings per share was -1.19.

    Revenue

    n/a
    		 42.07M

    Gross Profit

    n/a
    		 42.07M

    Operating Income

    n/a
    		 -145.59M

    Net Income

    n/a
    		 -130.3M

    EBITDA

    n/a
    		 -143.1M

    EBIT

    n/a
    		 -145.59M

    Earnings Per Share (EPS)

    n/a
    		 -1.19
    Full Income Statement

    Balance Sheet

    The company has 69.53M in cash and 36.49M in debt, giving a net cash position of 33.04M.

    Cash & Cash Equivalents

    n/a
    		 69.53M

    Total Debt

    n/a
    		 36.49M

    Net Cash

    n/a
    		 33.04M

    Retained Earnings

    n/a
    		 -501.56M

    Total Assets

    n/a
    		 274.31M

    Working Capital

    n/a
    		 189.01M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -131.5M and capital expenditures -754K, giving a free cash flow of -132.25M.

    Operating Cash Flow

    n/a
    		 -131.5M

    Capital Expenditures

    n/a
    		 -754K

    Free Cash Flow

    n/a
    		 -132.25M

    FCF Per Share

    n/a
    		 -1.21
    Full Cash Flow Statement

    Margins

    Gross margin is 94.06%, with operating and profit margins of -346.09% and -309.73%.

    Gross Margin

    n/a
    		 94.06%

    Operating Margin

    n/a
    		 -346.09%

    Pretax Margin

    n/a
    		 -309.24%

    Profit Margin

    n/a
    		 -309.73%

    EBITDA Margin

    n/a
    		 -346.09%

    EBIT Margin

    n/a
    		 -346.09%

    FCF Margin

    n/a
    		 -314.38%

    Dividends & Yields

    TNGX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for TNGX is $13, which is 176.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $13

    Price Target Difference

    n/a
    		 176.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.13

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist